Wealth Enhancement Trust Services’s Alnylam Pharmaceuticals ALNY Stock Holding History

Wealth Enhancement Trust Services’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.82K	Buy	+16	New	+$4.83K	﹤0.01%	846

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Wealth Enhancement Trust Services's ALNY Position: Q2 2026 in Review

Wealth Enhancement Trust Services opened a new position in Alnylam Pharmaceuticals (ALNY) in Q2 2026: 16 shares worth $4.82K. The stake represents ﹤0.01% of the portfolio and ranks #846 among its holdings.

587 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Wealth Enhancement Trust Services held 16 shares of Alnylam Pharmaceuticals worth $4.82K as of Q2 2026.
Alnylam Pharmaceuticals was a new Wealth Enhancement Trust Services position in Q2 2026.
Alnylam Pharmaceuticals made up ﹤0.01% of Wealth Enhancement Trust Services's portfolio in Q2 2026, its #846 holding.
587 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Wealth Enhancement Trust Services's 13F filing for Q2 2026, filed 15 Jul 2026.